Back to Search Start Over

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.

Authors :
Lai LY
Kaufman SR
Oerline MK
Caram MEV
Maganty A
Hollenbeck BK
Shahinian VB
Source :
JNCI cancer spectrum [JNCI Cancer Spectr] 2022 Mar 02; Vol. 6 (2).
Publication Year :
2022

Abstract

Urologists are increasingly prescribing oral targeted therapies to patients with advanced prostate cancer. Concurrent with this trend, urology practices are allowing patients to fill their prescription onsite or through a pharmacy established by the practice. We examined prescription patterns for abiraterone or enzalutamide between eventually dispensing single-specialty urology practices, nondispensing single-specialty urology practices, and multispecialty practices using a 20% random sample of the 2013-2017 national Medicare claims. We determined physician dispensing through manual search of publicly available information. From 2015 through 2017, higher percentages of patients managed by eventually dispensing single-specialty urology practices had a filled prescription of abiraterone or enzalutamide compared with patients managed in nondispensing single-specialty urology practices (eg, in 2017, 8.9%, 95% confidence interval = 7.3% to 10.9%, vs 5.9%, 95% confidence interval = 5.0% to 7.0%, respectively; 2-sided Pā€‰<ā€‰.001). Insofar as physician dispensing is associated with higher use of abiraterone or enzalutamide, it may represent a means to improve treatment access.<br /> (© The Author(s) 2022. Published by Oxford University Press.)

Details

Language :
English
ISSN :
2515-5091
Volume :
6
Issue :
2
Database :
MEDLINE
Journal :
JNCI cancer spectrum
Publication Type :
Academic Journal
Accession number :
35603854
Full Text :
https://doi.org/10.1093/jncics/pkac023